Your browser doesn't support javascript.
loading
A large-scale genetic analysis reveals a strong contribution of the HLA class II region to giant cell arteritis susceptibility.
Carmona, F David; Mackie, Sarah L; Martín, Jose-Ezequiel; Taylor, John C; Vaglio, Augusto; Eyre, Stephen; Bossini-Castillo, Lara; Castañeda, Santos; Cid, Maria C; Hernández-Rodríguez, José; Prieto-González, Sergio; Solans, Roser; Ramentol-Sintas, Marc; González-Escribano, M Francisca; Ortiz-Fernández, Lourdes; Morado, Inmaculada C; Narváez, Javier; Miranda-Filloy, José A; Beretta, Lorenzo; Lunardi, Claudio; Cimmino, Marco A; Gianfreda, Davide; Santilli, Daniele; Ramirez, Giuseppe A; Soriano, Alessandra; Muratore, Francesco; Pazzola, Giulia; Addimanda, Olga; Wijmenga, Cisca; Witte, Torsten; Schirmer, Jan H; Moosig, Frank; Schönau, Verena; Franke, Andre; Palm, Øyvind; Molberg, Øyvind; Diamantopoulos, Andreas P; Carette, Simon; Cuthbertson, David; Forbess, Lindsy J; Hoffman, Gary S; Khalidi, Nader A; Koening, Curry L; Langford, Carol A; McAlear, Carol A; Moreland, Larry; Monach, Paul A; Pagnoux, Christian; Seo, Philip; Spiera, Robert.
Afiliação
  • Carmona FD; Instituto de Parasitología y Biomedicina "López-Neyra," CSIC, PTS Granada, Granada 18016, Spain. Electronic address: dcarmona@ipb.csic.es.
  • Mackie SL; Leeds Institute of Rheumatic and Musculoskeletal Medicine and NIHR-Leeds Musculoskeletal Biomedical Research Unit, University of Leeds, Leeds LS7 4SA, UK.
  • Martín JE; Instituto de Parasitología y Biomedicina "López-Neyra," CSIC, PTS Granada, Granada 18016, Spain.
  • Taylor JC; School of Medicine and NIHR-Leeds Musculoskeletal Biomedical Research Unit, University of Leeds, Leeds LS9 7TF, UK.
  • Vaglio A; Unit of Nephrology, University Hospital of Parma, Parma 43126, Italy.
  • Eyre S; NIHR Manchester Musculoskeletal Biomedical Research Unit, Manchester Academy of Health Sciences, Manchester, UK; Arthritis Research UK Epidemiology Unit, University Of Manchester, Manchester M13 9NT, UK.
  • Bossini-Castillo L; Instituto de Parasitología y Biomedicina "López-Neyra," CSIC, PTS Granada, Granada 18016, Spain.
  • Castañeda S; Department of Rheumatology, Hospital de la Princesa, IIS-Princesa, Madrid 28006, Spain.
  • Cid MC; Vasculitis Research Unit, Department of Autoimmune Diseases, Hospital Clínic, University of Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona 08036, Spain.
  • Hernández-Rodríguez J; Vasculitis Research Unit, Department of Autoimmune Diseases, Hospital Clínic, University of Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona 08036, Spain.
  • Prieto-González S; Vasculitis Research Unit, Department of Autoimmune Diseases, Hospital Clínic, University of Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona 08036, Spain.
  • Solans R; Autoimmune Systemic Diseases Unit, Department of Internal Medicine, Hospital Vall d'Hebron, Autonomous University of Barcelona, Barcelona 08035, Spain.
  • Ramentol-Sintas M; Autoimmune Systemic Diseases Unit, Department of Internal Medicine, Hospital Vall d'Hebron, Autonomous University of Barcelona, Barcelona 08035, Spain.
  • González-Escribano MF; Department of Immunology, Hospital Universitario Virgen del Rocío (IBiS, CSIC, US), Sevilla 41013, Spain.
  • Ortiz-Fernández L; Department of Immunology, Hospital Universitario Virgen del Rocío (IBiS, CSIC, US), Sevilla 41013, Spain.
  • Morado IC; Department of Rheumatology, Hospital Clínico San Carlos, Madrid 28040, Spain.
  • Narváez J; Department of Rheumatology, Hospital Universitario de Bellvitge-IDIBELL, L'Hospitalet de Llobregat, Barcelona 08907, Spain.
  • Miranda-Filloy JA; Department of Rheumatology, Hospital Xeral-Calde, Lugo 27004, Spain.
  • Beretta L; Referral Center for Systemic Autoimmune Diseases, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico di Milano, Milan 20122, Italy.
  • Lunardi C; Department of Medicine, Universita degli Studi di Verona, Verona 37134, Italy.
  • Cimmino MA; Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, Genova 16132, Italy.
  • Gianfreda D; Department of Clinical and Experimental Medicine, University of Parma, School of Medicine, Parma 43126, Italy.
  • Santilli D; Unit of Internal Medicine and Rheumatology, University Hospital of Parma, Parma 43126, Italy.
  • Ramirez GA; Unit of Internal Medicine and Immunology, IRCCS Ospedale San Raffaele and Università Vita-Salute San Raffaele, Milan 20132, Italy.
  • Soriano A; Department of Clinical Medicine and Rheumatology, Campus Bio-Medico University, Rome 00128, Italy.
  • Muratore F; Rheumatology Unit, Department of Internal Medicine, Azienda Ospedaliera Arcispedale Santa Maria Nuova, Istituto di Ricovero e Cura a Carattere Scientifico, Reggio Emilia 42123, Italy.
  • Pazzola G; Rheumatology Unit, Department of Internal Medicine, Azienda Ospedaliera Arcispedale Santa Maria Nuova, Istituto di Ricovero e Cura a Carattere Scientifico, Reggio Emilia 42123, Italy.
  • Addimanda O; Rheumatology Unit, Department of Internal Medicine, Azienda Ospedaliera Arcispedale Santa Maria Nuova, Istituto di Ricovero e Cura a Carattere Scientifico, Reggio Emilia 42123, Italy.
  • Wijmenga C; Department of Genetics, University of Groningen, University Medical Center Groningen, Groningen 9700, the Netherlands.
  • Witte T; Hannover Medical School, Hannover 30625, Germany.
  • Schirmer JH; Vasculitis Clinic, Klinikum Bad Bramstedt & University Hospital of Schleswig Holstein, Bad Bramstedt 24576, Germany.
  • Moosig F; Vasculitis Clinic, Klinikum Bad Bramstedt & University Hospital of Schleswig Holstein, Bad Bramstedt 24576, Germany.
  • Schönau V; Department of Rheumatology and Immunology, Universitätsklinikum Erlangen, Erlangen 91054, Germany.
  • Franke A; Institute of Clinical Molecular Biology, Christian-Albrechts-University of Kiel, Kiel 24105, Germany.
  • Palm Ø; Department of Rheumatology, Oslo University Hospital, Oslo 0424, Norway.
  • Molberg Ø; Department of Rheumatology, Oslo University Hospital, Oslo 0424, Norway.
  • Diamantopoulos AP; Department of Rheumatology, Hospital of Southern Norway Trust, Kristiansand 4604, Norway.
  • Carette S; Division of Rheumatology, Mount Sinai Hospital, Toronto, ON M5T 3L9, Canada.
  • Cuthbertson D; Department of Biostatistics, University of South Florida, Tampa, FL 33612, USA.
  • Forbess LJ; Division of Rheumatology, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA.
  • Hoffman GS; Center for Vasculitis Care and Research, Cleveland Clinic Foundation, Cleveland, OH 44195, USA.
  • Khalidi NA; Division of Rheumatology, St. Joseph's Healthcare, McMaster University, Hamilton, ON L8N 1Y2, Canada.
  • Koening CL; Division of Rheumatology, University of Utah, Salt Lake City, UT 84132, USA.
  • Langford CA; Center for Vasculitis Care and Research, Cleveland Clinic Foundation, Cleveland, OH 44195, USA.
  • McAlear CA; Penn Vasculitis Center, Division of Rheumatology, University of Pennsylvania, Philadelphia, PA 19104, USA.
  • Moreland L; Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA 15261, USA.
  • Monach PA; Section of Rheumatology, Boston University School of Medicine, Boston, MA 02118, USA.
  • Pagnoux C; Division of Rheumatology, Mount Sinai Hospital, Toronto, ON M5T 3L9, Canada.
  • Seo P; Division of Rheumatology, Johns Hopkins University, Baltimore, MD 21224, USA.
  • Spiera R; Department of Rheumatology, Hospital for Special Surgery, New York, NY 10021, USA.
Am J Hum Genet ; 96(4): 565-80, 2015 Apr 02.
Article em En | MEDLINE | ID: mdl-25817017
ABSTRACT
We conducted a large-scale genetic analysis on giant cell arteritis (GCA), a polygenic immune-mediated vasculitis. A case-control cohort, comprising 1,651 case subjects with GCA and 15,306 unrelated control subjects from six different countries of European ancestry, was genotyped by the Immunochip array. We also imputed HLA data with a previously validated imputation method to perform a more comprehensive analysis of this genomic region. The strongest association signals were observed in the HLA region, with rs477515 representing the highest peak (p = 4.05 × 10(-40), OR = 1.73). A multivariate model including class II amino acids of HLA-DRß1 and HLA-DQα1 and one class I amino acid of HLA-B explained most of the HLA association with GCA, consistent with previously reported associations of classical HLA alleles like HLA-DRB1(∗)04. An omnibus test on polymorphic amino acid positions highlighted DRß1 13 (p = 4.08 × 10(-43)) and HLA-DQα1 47 (p = 4.02 × 10(-46)), 56, and 76 (both p = 1.84 × 10(-45)) as relevant positions for disease susceptibility. Outside the HLA region, the most significant loci included PTPN22 (rs2476601, p = 1.73 × 10(-6), OR = 1.38), LRRC32 (rs10160518, p = 4.39 × 10(-6), OR = 1.20), and REL (rs115674477, p = 1.10 × 10(-5), OR = 1.63). Our study provides evidence of a strong contribution of HLA class I and II molecules to susceptibility to GCA. In the non-HLA region, we confirmed a key role for the functional PTPN22 rs2476601 variant and proposed other putative risk loci for GCA involved in Th1, Th17, and Treg cell function.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Arterite de Células Gigantes / Genes MHC da Classe II / Herança Multifatorial Tipo de estudo: Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Humans Idioma: En Ano de publicação: 2015 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Arterite de Células Gigantes / Genes MHC da Classe II / Herança Multifatorial Tipo de estudo: Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Humans Idioma: En Ano de publicação: 2015 Tipo de documento: Article